‘Formal review’ of GP access arrangements needed, says Healthwatch
UK-based charity conducted a review of GP access between April 2019 and December 2020
22nd March 2021
Latest news
NICE recommends Kyprolis triple combination treatment for multiple myeloma
Kyprolis plus lenalidomide and dexamethasone approved as a second-line treatment
22nd March 2021
Roche’s Tecentriq improves disease-free survival in early lung cancer
Tecentriq is approved in five lung cancer indications currently
22nd March 2021
Havas Lynx and Syneos take home most agency Golds at PM Society awards
On the client side, AstraZeneca came out on top with four Golds, one Silver and one Bronze awards
19th March 2021
EU authorisation for XPhyto’s rapid COVID-19 PCR test
PCR-based test has a sample collection to result time of 25 minutes
19th March 2021
ICR’s ‘resistance-busting’ drug advances into Phase I trial
EP0042 is a dual-inhibitor drug designed to block the activity of two cancer-driving proteins
19th March 2021
NICE approves Lynparza plus Avastin via Cancer Drugs Fund
Genomic HRD testing to be launched to support the introduction of this treatment regimen
19th March 2021
UK and EU regulators reaffirm the safety of AZ/Oxford Uni’s COVID-19 vaccine
MHRA and EMA conclude the vaccine's benefits continue to outweigh risks
19th March 2021
GSK launches late-stage study of long-acting antibody for severe asthma
GSK’294 is designed to deliver long-acting suppression of IL-5 in severe eosinophilic asthma patients
18th March 2021
UK approval for Daiichi Sankyo’s cholesterol-lowering treatments
In the UK, over seven million people are affected by cardiovascular disease
18th March 2021
NICE backs AstraZeneca’s Calquence for CLL
Recommendation offers new chemotherapy-free treatment options for these patients
18th March 2021
UK gene therapy hub network awarded £18m in funding
Hubs will be located at King’s College London, NHS Blood and Transplant in Bristol and the University of Sheffield
18th March 2021
HRA Pharma Rare Diseases funds online hub for Cushing’s Syndrome
Cushing's Syndrome is rare and severe condition caused by prolonged high levels of cortisol in the blood
17th March 2021
Priority review for Merck & Co’s belzutifan in rare kidney cancer subset
Belzutifan is a potential treatment for von Hippel-Lindau disease-associated renal cell carcinoma
17th March 2021
Lilly’s mirikizumab hits primary endpoint in ulcerative colitis study
Patients treated with monoclonal antibody achieved clinical remission at week 12
17th March 2021
